Discovery of Alogliptin: A Potent, Selective, Bioavailable, and Efficacious Inhibitor of Dipeptidyl Peptidase IV
Journal of Medicinal Chemistry2007Vol. 50(10), pp. 2297–2300
Citations Over TimeTop 1% of 2007 papers
Jun Feng, Zhiyuan Zhang, Michael B. Wallace, Jeffrey A. Stafford, Stephen W. Kaldor, Daniel B. Kassel, Marc Navre, Lihong Shi, R.J. Skene, Tomoko Asakawa, Koji Takeuchi, Rongda Xu, David R. Webb, Stephen L. Gwaltney
Abstract
Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4). Herein, we describe the structure-based design and optimization of alogliptin and related quinazolinone-based DPP-4 inhibitors. Following an oral dose, these noncovalent inhibitors provide sustained reduction of plasma DPP-4 activity and a lowering of blood glucose in animal models of diabetes. Alogliptin is currently undergoing phase III trials in patients with type 2 diabetes.
Related Papers
- → Ameliorating effect of the novel dipeptidyl peptidase‐4 inhibitor teneligliptin on psoriasis: A report of two cases(2015)18 cited
- → Vildagliptin, a dipeptidyl peptidase-4 inhibitor, ameliorates the development of CaCl2-induced abdominal aortic aneurysm in mice via anti-inflammatory effects(2013)3 cited
- → Apple and banana displayed better inhibition of dipeptidyl peptidase IV activity than vildagliptin(2018)1 cited
- → Dynamics of switching, adherence, and persistence of dipeptidyl peptidase-4 inhibitors use: A nationwide cohort study(2019)1 cited
- → SYSTEMATIC LITERATURE REVIEW ON CLINICAL EFFICACY AND SAFETY OF ALOGLIPTIN IN COMPARISON WITH VILDAGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN AND SITAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS(2015)